Back to search

National and Kapodistrian University of Athens

Η έκφραση της Ε3, Ε4 λιγάσης ουβικουϊτίνης UBE4B στον καρκίνο

Abstract

dc:description

Homeodynamics is a fundamental feature of single and multi-cellular organisms that is maintained by convenient cellular counteractions to a plethora of deleterious intrinsic and extrinsic signals (Lloyd, Aon et al. 2001). Aberrations in the modulating pathways that govern these responses result in excess of damage, functional defects and disease such as cancer (Gorgoulis and Halazonetis 2010). In cancer cells, one of the most frequently affected cellular functions is the proper execution of the cell cycle that under conditions can impose genomic instability (Negrini, Gorgoulis et al. 2010). In the last years, the latter has been established as one of the hallmarks of cancer cells (Hanahan and Weinberg 2011). One biological process which has been demonstrated to be directly compatible with replication stress is the oncogene induced cellular proliferation (Halazonetis, Gorgoulis et al. 2008). Under normal circumstances, as soon as any DNA lesion has been detected, various proteins which regulate cell cycle are getting activated in order to trigger the stop of cell cycle progression. These proteins are in the service of a sophisticated response mechanism against genomic alterations which is called DNA Damage Response (DDR)(Jackson and Bartek 2009). In case DNA lesions cannot be repaired, the cell is driven to apoptosis or senescence. Both procedures are able to potentially function as tumor barriers (Jackson and Bartek 2009). Post-translational modifications constitute and important strategy of the cell in order to respond dynamically to intrinsic or environmental changes caused by growth factors, stressors or differentiation signals (Weissman 2001). Protein modifications can be induced through diverse processes such as methylation, acetylation, hydroxylation, phosphorylation, ubiquitination or via the conjugation of ubiquitin-like(Ubl) proteins (Weissman 2001, Sun and Chen 2004).Ubiquitination is a type of post-translational modification considered as an essential cellular mechanism which plays a significant role in various operations such as cellular proliferation and growth, DNA repair, transcriptional regulation, internal signal transition, autophagy, cell cycle and apoptosis (Hershko and Ciechanover 1998, Chondrogianni and Gonos 2012, Streich and Lima 2014). Ubiquitin system was initially discovered as a mechanism which targets defective proteins for degradation through the proteasome (Ravid and Hochstrasser 2008). Since ubiquitination is a multistep process, it is implemented by different enzymes named Ε1, Ε2, Ε3 ubiquitin ligases which aim to drive marked proteins with ubiquitin moieties to proteasome-dependent degradation (Shenoy 2007, Hoeller and Dikic 2009, Berndsen and Wolberger 2014).A number ofΕ3 ligases have been linked with cancer growth mainly due to their ability to promote the degradation of oncogenes or tumor suppressive factors (Hoeller, Hecker et al. 2006, Nakayama and Nakayama 2006, Bernassola, Karin et al. 2008). E3 ligases are discriminated in proportion to the structure of their catalytic domain in three main categories which are HECT, RING και U-BOX (Ardley and Robinson 2005). Well-documented E3 ligases with oncogenic role are, RING-type Hdm2, an important negative regulator of the tumor suppressor p53 as well as the SCF ligases (they include many subunits), which regulate cell cycle progression. Depending on their substrate selectivity every E3 ligase is able to act either promoting oncogenesis or halting it while enzyme’s behavior may be diversified depending also on the type of the tissue where it is expressed (Bond, Hu et al. 2005, Vousden and Prives 2005). The E4B (UBE4B) ubiquitination factor in human is the homolog protein of UFD2 which has been found in Saccharomyces cerevisiae (Hatakeyama, Yada et al. 2001, Caren, Holmstrand et al. 2006). UBE4Bgeneislocatedinthesmallarmofchromosome 1 and is considered as a possible tumor suppressor in neuroblastoma, a type of cancer which affects the sympathetic nervous system in childhood (Caren, Holmstrand et al. 2006). The human UBE4B/UFD2a is a newly identified E3 ubiquitin ligase which includes a U-BOX type catalytic domain (Hatakeyama, Yada et al. 2001). Its homolog protein in yeast, UFD2, is involved in a not so recently described degradation pathway via proteasome namely UFD (ubiquitin fusion degradation) pathway (Johnson, Ma et al. 1995). Later a new family of ubiquitin ligases was discovered, which is called E4 and where UFD2 has been enrolled (Koegl, Hoppe et al. 1999).Unless the well documented E3 ligases which mono-ubiquitinate or multi-mono-ubiquitinate their substrates, E4 ligases in collaboration with the rest ligases catalyze the extension of the existed oligoubiquitin chain on the substrate (Park, Yoon et al. 2009, McDowell and Philpott 2013). According to recent data, UBE4B has been found to be over expressed in the majority of patients with both breast and liver cancer (Zhang, Lv et al. 2014, Zhang, Pan et al. 2016). There are also indications that UBE4B functions as an oncogenic factor and is linked with one of the most common characteristics of cancer cells which is their resistance to apoptosis. It has been shown that in a variety of human cell lines, UBE4B interacts with the negative regulator of the pro-apoptotic factor p53, HDM2 (Ε3 ligase) and triggers the poly-ubiquitination of p53 in order to transmit to the proteasome for degradation (Wu, Pomeroy et al. 2011, Zhang, Lv et al. 2014). The oncogenic role of UBE4B is supported by the fact that upon induction of DNA damage via γ-radiation in cancer cell lines, UBE4B polyubiquitinates the phosphorylated p53 at Serine 15 and 392. The latter protein is well-known as the genome “guardian” of the cell and its phosphorylated form at the aforementioned sites usually leads to the cancelation of cell cycle progression in order the damage to get repaired (Du, Wu et al. 2016).Finally, the homolog protein of hUBE4B in Caenorhabditis elegans is correlated with two essential biological processes for cancer’s development and progress namely apoptosis and homologous recombination (HR). The latter constitutes one of the basic DNA repair mechanisms with regard to Double Strand Breaks (DSBs). It is noteworthy that UBE4B acts as a mediator molecule contributing to the interconnection between apoptosis and HR following DNA damage occurrence in order to prevent them from being active simultaneously (Ackermann, Schell et al. 2016). The herein PhD thesis is focused on the investigation of UBE4B’s expression and role in the progression and development of cancer, in coordination with apoptosis, DDR and DNA repair. In the current study there were used both in vitro (cancerous and normal cell lines) and in vivo (human tissue biopsies) biological systems. Among the latter there were employed colon cancer tissues that represented all the stages of carcinogenesis, in order to clarify how much early in carcinogenesis is UBE4B expressed and if it finally plays an oncogenic or tumor suppressor role. The study was performed through the application of biochemical, molecular methods along with methods of optical microscopy. More particularly, in the frame of the current PhD thesis there were examined the following scientific questions: 1) Which is the expression of Ε3/Ε4 UBE4B ligase in vivo (human tissue biopsies) in colon and lung cancer? 2) Is there any correlation between UBE4B and the protein expression levels of its main substrate wild type p53 in human colon and lung cancer tissues? 3) What is the cause of UBE4B’s increase regarding its protein levels which was detected in the majority of the studied tissues, in the malignant areas compared to their neighboring normal one? 4) Is UBE4B expressed in preliminary stages during carcinogenesis in human colon as well as head and neck? 5) What does it happen with the expression of UBE4B ligase in cancer cell lines upon induction of DNA Damage? Is it somehow implicated in DNA repair and apoptosis? Τhe answers to the above queries are presented in Chapter 3. Taking all into consideration, this dissertation offers justified evidence that render UBE4B a new and potentially candidate oncogenic factor which is overexpressed even from the early benign stages in the progression of colon and lung cancer. This observation seems to happen due to UBE4B’s elevated mRNA levels or to post-translational modifications in protein level. In accordance to other scientific reports which are focused on the investigation of UBE4B’s role in repair mechanisms, this specific PhD thesis demonstrates UBE4B as an essential player in view of DDR network and molecular carcinogenesis as well. All in all, further elucidation as far as the role of E3/E4 UBE4B ubiquitin ligase in carcinogenesis is necessary while it constitutes a novel and promising research field which could enhance the participation of this protein in future therapeutic intervention with a possibly important clinical effect.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2020

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Antoniou, Nikolaos
  • Αντωνίου, Νικόλαος

Subjects

dc:subject × 12

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/46951

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Antoniou, Nikolaos; Αντωνίου, Νικόλαος. Η έκφραση της Ε3, Ε4 λιγάσης ουβικουϊτίνης UBE4B στον καρκίνο. National and Kapodistrian University of Athens, 2020. http://hdl.handle.net/10442/hedi/46951